^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    14d
    READAPT: A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA (clinicaltrials.gov)
    P=N/A, N=2239, Completed, University of L'Aquila | Recruiting --> Completed | N=1067 --> 2239
    Trial completion • Enrollment change
    16d
    POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy (clinicaltrials.gov)
    P2, N=200, Recruiting, St. Antonius Hospital | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    16d
    NUANCE-ICAD: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection Vs Conventional Clopidogrel Therapy in Symptomatic ICAD (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Sunnybrook Health Sciences Centre
    New trial
    28d
    Precision PCI Registry (clinicaltrials.gov)
    P=N/A, N=1643, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    1m
    Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington State University
    New P1 trial
    1m
    SWAP-7: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (clinicaltrials.gov)
    P4, N=48, Not yet recruiting, University of Florida
    New P4 trial
    1m
    Dual Antiplatelet Therapy Adherence With Reminder App Usage (clinicaltrials.gov)
    P=N/A, N=9, Terminated, Montefiore Medical Center | N=68 --> 9 | Trial completion date: Dec 2030 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2030 --> Jul 2024; The PI is discontinuing the study since the platform/Application is no longer available for use. Study terminated effective 7/29/2024.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Adherence
    1m
    TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. (PubMed, Drug Resist Updat)
    Mechanistically, TMOD3 promoted F-actin polymerization, thereby facilitating the fusion of autophagosomes with lysosomes, increasing the degradation of the ACSL4 protein, and augmenting the ferroptosis-inducing effects of RSL3...Cangrelor, an FDA-approved drug, can target TMOD3...In conclusion, TMOD3 was found to inhibit ferroptosis and induced the resistance to PD-1 antibody by facilitating the fusion of autophagosomes and lysosomes through the promotion of F-actin polymerization in KRAS-mutant PC. TMOD3 was identified as a novel target for PC therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
    |
    RSL3
    1m
    Study on Effect of Pharmacogenomics-based Point-of-Care Testing on Guiding Precise Antiplatelet and Lipid-lowering Therapies for Acute Ischemic Stroke Patients after rtPA Thrombolysis (ChiCTR2400090813)
    P=N/A, N=1092, Not yet recruiting, Dalian Municipal Central Hospital; Dalian Municipal Central Hospital
    New trial
    |
    atorvastatin
    1m
    Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with cute minor ischemic stroke with CYP2C19 gene function deficiency: A multicenter, open label, and efficacy randomized controlled study (ChiCTR2400091121)
    P4, N=1050, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New P4 trial
    |
    aspirin
    1m
    BRLCEIACS/OMI: Brilinta Clinical Experience Investigation (clinicaltrials.gov)
    P=N/A, N=663, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Mar 2028 --> Jul 2024 | Trial primary completion date: Mar 2028 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date
    2ms
    ODIN: One-Month DAPT in CABG Patients (clinicaltrials.gov)
    P3, N=700, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    2ms
    Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST) (clinicaltrials.gov)
    P4, N=1022, Completed, General Hospital of Shenyang Military Region | Recruiting --> Completed
    Trial completion
    2ms
    A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial (clinicaltrials.gov)
    P4, N=3200, Active, not recruiting, Yonsei University
    Trial completion date • Trial primary completion date
    2ms
    Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Yonsei University | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    2ms
    DEDAPT-TICA: Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke (clinicaltrials.gov)
    P2/3, N=100, Not yet recruiting, Mazandaran University of Medical Sciences
    New P2/3 trial
    |
    aspirin
    2ms
    Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial (clinicaltrials.gov)
    P=N/A, N=3744, Recruiting, Yonsei University | Trial completion date: Jul 2025 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    2ms
    Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report. (PubMed, Cureus)
    Antiplatelet therapy was started with acetylsalicylic acid 100 mg and clopidogrel 75 mg once a day. With the recommendation of hematology, cytoreductive treatment, hydroxyurea 1000 mg twice a day, was started. The patient's complaints were resolved at the end of the second day, and the patient with minimal ataxia was discharged with recommendations. Patients with ET should be aware of ischemic cerebrovascular disease and consider antiplatelet and cytoreductive treatment options.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    JAK2 V617F • JAK2 mutation
    |
    hydroxyurea
    2ms
    APS-STROKE: Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (clinicaltrials.gov)
    P4, N=200, Recruiting, Seoul National University Hospital | N=400 --> 200 | Trial completion date: Oct 2028 --> Mar 2029 | Trial primary completion date: Jul 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, University of Alberta
    New P2 trial
    2ms
    A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants (clinicaltrials.gov)
    P1, N=28, Completed, AstraZeneca | Recruiting --> Completed
    Trial completion
    2ms
    ACLO-TAVR: Aspirin vs Clopidogrel After TAVR (clinicaltrials.gov)
    P=N/A, N=230, Recruiting, Yonsei University | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    aspirin
    2ms
    OPTIMUS-7: Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus (clinicaltrials.gov)
    P4, N=105, Completed, University of Florida | Active, not recruiting --> Completed
    Trial completion
    |
    aspirin
    3ms
    VCP1-III-01: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) (clinicaltrials.gov)
    P3, N=1000, Recruiting, Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    Ticagrelor and Statins: Dangerous Liaisons? (PubMed, Cardiovasc Drugs Ther)
    Statins have different pharmacokinetic profiles; some undergo CYP3A4-mediated metabolism; rosuvastatin is primarily metabolized by the CYP2C9; and they have different affinities for drug transporters...Large pharmacovigilance and small observational studies reported increased rhabdomyolysis in patients treated with some statins and ticagrelor but not aspirin, clopidogrel or prasugrel. Recent studies in vitro, pharmacokinetic trials and in silico drug modelling identified and validated the BCRP inhibition by ticagrelor, as a mechanism contributing to the DDI with statins, as 'victim' drugs, leading to increased rhabdomyolysis. While the clinical impact of this DDI deserves further investigation, a careful evaluation should be advised when ticagrelor is co-prescribed with some statins.
    Journal
    |
    CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    3ms
    Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST) (clinicaltrials.gov)
    P4, N=1022, Recruiting, General Hospital of Shenyang Military Region | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Nov 2024
    Trial completion date • Trial primary completion date
    3ms
    CAPTT: Colonoscopy and Antiplatelet Therapy Trial (clinicaltrials.gov)
    P4, N=100, Not yet recruiting, Ochsner Health System
    New P4 trial
    |
    aspirin
    3ms
    Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=870, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    POLY-ACS: Polypill in Acute Coronary Syndrome (clinicaltrials.gov)
    P2, N=120, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    3ms
    TACSI: Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome (clinicaltrials.gov)
    P4, N=2203, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting | Trial completion date: Jun 2031 --> Feb 2035
    Enrollment closed • Trial completion date
    |
    aspirin
    3ms
    A randomized controlled study to evaluate the Short-term anticoagulation strategy after TAVR for Prevention Subclinical leaflet thrombosis (SCOPE) (ChiCTR2400087453)
    P4, N=454, Not yet recruiting, Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Capital Medical University
    New P4 trial
    3ms
    CAPTIVA: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (clinicaltrials.gov)
    P3, N=1683, Recruiting, University of Florida | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2027 --> May 2028
    Trial completion date • Trial primary completion date
    3ms
    Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=870, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    The Switching Antiplatelet-9 (SWAP-9) Study (clinicaltrials.gov)
    P4, N=90, Not yet recruiting, University of Florida
    New P4 trial
    3ms
    Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    4ms
    TAPIS: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke (clinicaltrials.gov)
    P3, N=1380, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    4ms
    IMAGE-AF: Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, University in Zielona Góra
    New trial • Predictive model
    4ms
    Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Jiangsu vcare pharmaceutical technology co., LTD
    New P3 trial